Physician profile
Victor A Oderinde
NPI 1861486482
$6,120.47
in general payments reported to CMS, 2019-2025
9 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2021: $119 · 2022: $52.24 · 2023: $5,470 · 2024: $28.31 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $5,304 · Food and Beverage: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $5,304.24 |
| Food and Beverage | $320.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $5,304.24 | 2023 | Neurostar Tms Therapy System |
| Alkermes, INC. | $347.98 | 2019-2023 | Lybalvi |
| Teva Pharmaceuticals USA, INC. | $171.34 | 2023-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $107.78 | 2019-2023 | Invega Sustenna |
| Allergan, INC. | $84.15 | 2019 | |
| Shire North American Group INC | $41.09 | 2019 | |
| Lundbeck LLC | $32.42 | 2019 | |
| Indivior INC. | $17.93 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Oderinde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.